{"log_id": 5426947312563630240, "direction": 0, "words_result_num": 36, "words_result": [{"probability": {"variance": 0.019246, "average": 0.914691, "min": 0.557003}, "location": {"width": 800, "top": 294, "height": 54, "left": 322}, "words": "度F降约25%,但二药台用的降脂效大于单一药物使用的降指效果"}, {"probability": {"variance": 0.023518, "average": 0.909256, "min": 0.475224}, "location": {"width": 1001, "top": 347, "height": 59, "left": 368}, "words": "抗酸剂:本品与含有氢氧化镁和氢氧化铝的口服抗酸药混悬这合用时,阿托伐他江的血"}, {"probability": {"variance": 0.032064, "average": 0.901366, "min": 0.35438}, "location": {"width": 768, "top": 400, "height": 52, "left": 322}, "words": "液度下降约35%,但其降低低密度脂蛋白胆醉的作用未受影响"}, {"probability": {"variance": 0.014005, "average": 0.950583, "min": 0.410937}, "location": {"width": 985, "top": 454, "height": 57, "left": 368}, "words": "华法林:本品与华法林合,凝血酶原时间在最初几天内轻度下降,15天后恢复正需"}, {"probability": {"variance": 0.010784, "average": 0.947865, "min": 0.505296}, "location": {"width": 612, "top": 505, "height": 48, "left": 315}, "words": "即便如此,服用华头林的患者加服本品时应严密监测"}, {"probability": {"variance": 0.014249, "average": 0.912501, "min": 0.535249}, "location": {"width": 905, "top": 557, "height": 57, "left": 358}, "words": "氨替比林:木品多个剂星与氨替比林联合用约时未发现对氨替比林清除的影响"}, {"probability": {"variance": 0.037404, "average": 0.873859, "min": 0.41885}, "location": {"width": 912, "top": 610, "height": 57, "left": 361}, "words": "西咪替丁:有关本马与西珠丁相互作用的研究未发现二之间存相工作用"}, {"probability": {"variance": 0.016832, "average": 0.933383, "min": 0.471187}, "location": {"width": 1003, "top": 663, "height": 59, "left": 356}, "words": "氮氯地平:在健受试者中进行的药物相互作用研究中,阿托伐他汀80mg和氨氯地平"}, {"probability": {"variance": 0.026065, "average": 0.83663, "min": 0.512791}, "location": {"width": 496, "top": 715, "height": 45, "left": 317}, "words": "0mng合用可使阿伐他汀的暴露增加18%"}, {"probability": {"variance": 0.014801, "average": 0.94593, "min": 0.363351}, "location": {"width": 980, "top": 768, "height": 57, "left": 354}, "words": "夫西地酸:目前尚未开展阿伐他汀与夫西地酸的相互作用究。与其他他汀类药物"}, {"probability": {"variance": 0.015728, "average": 0.92696, "min": 0.555326}, "location": {"width": 1053, "top": 816, "height": 61, "left": 306}, "words": "样,在合井使用阿托伐他汀和夫西地酸的二市后经验中,已有肌肉相关事件的报道:和"}, {"probability": {"variance": 0.02548, "average": 0.91779, "min": 0.401437}, "location": {"width": 1049, "top": 871, "height": 57, "left": 306}, "words": "纹肌济解症,这一相互作用的制不明确、必须对患者进行密切监测,适当可暂停使用阿"}, {"probability": {"variance": 0.000106, "average": 0.990561, "min": 0.973876}, "location": {"width": 107, "top": 925, "height": 32, "left": 306}, "words": "托伐他汀"}, {"probability": {"variance": 0.00885, "average": 0.939942, "min": 0.627619}, "location": {"width": 1003, "top": 973, "height": 61, "left": 347}, "words": "其它:本品与降压药物或降糖药物合的床试验中,未发现有临床意义的药物相互作"}, {"probability": {"variance": 0, "average": 0.999098, "min": 0.999098}, "location": {"width": 34, "top": 1028, "height": 34, "left": 301}, "words": "用"}, {"probability": {"variance": 0.001925, "average": 0.960325, "min": 0.884343}, "location": {"width": 150, "top": 1079, "height": 34, "left": 308}, "words": "药物过量"}, {"probability": {"variance": 0.009249, "average": 0.95334, "min": 0.628564}, "location": {"width": 1001, "top": 1129, "height": 61, "left": 347}, "words": "本品药物过尚无特殊治疗措施一旦出现药物过敏,病人应根据需要采取对症治疗及"}, {"probability": {"variance": 0.016218, "average": 0.933031, "min": 0.503912}, "location": {"width": 1053, "top": 1182, "height": 61, "left": 297}, "words": "支持性措旅以供要器官的功能。应检查患者的功能和监测血清肌酸磷酸激酶水平。由"}, {"probability": {"variance": 0.0203, "average": 0.938729, "min": 0.401764}, "location": {"width": 882, "top": 1234, "height": 57, "left": 294}, "words": "于阿托伐他汀与血浆蛋白广泛结合,液透析不能明显加速本品从体内清除"}, {"probability": {"variance": 0.002673, "average": 0.957633, "min": 0.86968}, "location": {"width": 134, "top": 1291, "height": 32, "left": 317}, "words": "药理毒理"}, {"probability": {"variance": 2.2e-05, "average": 0.979337, "min": 0.974723}, "location": {"width": 84, "top": 1342, "height": 34, "left": 340}, "words": "药效学"}, {"probability": {"variance": 0.037024, "average": 0.882668, "min": 0.416732}, "location": {"width": 489, "top": 1392, "height": 45, "left": 336}, "words": "阿托伐汀属于 hmg-coa还原酶排制剂"}, {"probability": {"variance": 0.005463, "average": 0.797603, "min": 0.72369}, "location": {"width": 160, "top": 1403, "height": 64, "left": 1220}, "words": " P HARMNACEUT"}, {"probability": {"variance": 0.022508, "average": 0.920806, "min": 0.419541}, "location": {"width": 1239, "top": 1438, "height": 93, "left": 338}, "words": "阿托伐他汀是 hmg-coa还原醇的选择性、竞争制剂 hmg-coa还怎为限】令"}, {"probability": {"variance": 0.028802, "average": 0.83896, "min": 0.397332}, "location": {"width": 1102, "top": 1492, "height": 75, "left": 292}, "words": "的:该酶将3羟基3甲基戊二酰酶A转化为甲羟戈酸(包括胆质在凹醇的前德公司"}, {"probability": {"variance": 0.019778, "average": 0.89494, "min": 0.505681}, "location": {"width": 1028, "top": 1545, "height": 66, "left": 290}, "words": "胆固醇和甘油三在肝脏内合并成极低密度脂蛋白胆回醇(VLDL)并放到中以进"}, {"probability": {"variance": 0.016704, "average": 0.918807, "min": 0.447749}, "location": {"width": 1051, "top": 1598, "height": 61, "left": 288}, "words": "步输送至周围织低密度蛋白胆醇(LDL)中极低密脂蛋白胆固醇(VLDL)形成"}, {"probability": {"variance": 0.011165, "average": 0.942712, "min": 0.571402}, "location": {"width": 717, "top": 1653, "height": 50, "left": 288}, "words": "并主要通过受体对高亲和力的低密度蛋白(LDL)分解代谢"}, {"probability": {"variance": 0, "average": 0.709113, "min": 0.709113}, "location": {"width": 160, "top": 1659, "height": 38, "left": 1252}, "words": " FWAAMACEUT"}, {"probability": {"variance": 0.040344, "average": 0.852329, "min": 0.404052}, "location": {"width": 1083, "top": 1703, "height": 61, "left": 331}, "words": "阿托伐他汀通过拍制肝脏大 mgi-coa还原酶及固的生物合成从百降低症浆中圈一"}, {"probability": {"variance": 0.017153, "average": 0.921517, "min": 0.53829}, "location": {"width": 1111, "top": 1755, "height": 57, "left": 281}, "words": "醇和血清指蛋白液度,并过增加细孢表面的肝脏LDL受体数日以增强T的摄取和代,公司"}, {"probability": {"variance": 0.018591, "average": 0.920581, "min": 0.430376}, "location": {"width": 1001, "top": 1808, "height": 59, "left": 331}, "words": "阿托伐他汀也能降低低密度脂蛋白肛醇的生成和低帝度脂蛋白胆固萨的粒数阿托"}, {"probability": {"variance": 0.017215, "average": 0.936553, "min": 0.351799}, "location": {"width": 1053, "top": 1861, "height": 61, "left": 281}, "words": "伐他汀导低密度白胆固醇受体活性品著和持久性增加,进而循环中的低密度脂蛋白胆"}, {"probability": {"variance": 0.016927, "average": 0.932986, "min": 0.420448}, "location": {"width": 1049, "top": 1913, "height": 59, "left": 278}, "words": "固颗粒质量发生有益变化阿托汀可有效降低纯合子家族高固血患的低蜜"}, {"probability": {"variance": 0.012651, "average": 0.960924, "min": 0.475625}, "location": {"width": 722, "top": 1963, "height": 54, "left": 278}, "words": "度酯蛋白胆醇水平,通常降脂类药物对这类患者的疗效不住"}, {"probability": {"variance": 0.027639, "average": 0.84273, "min": 0.613058}, "location": {"width": 219, "top": 2023, "height": 34, "left": 315}, "words": "临床前安全性资"}], "language": 3}